Inhibikase Therapeutics develops IKT-001, an oral drug candidate for pulmonary arterial hypertension, a rare lung blood vessel disease. IKT reports earnings on Fri, Nov 13, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 13 | Chardan Capital | Initiated | Hold | |
| Aug 16 | HC Wainwright & Co. | Maintained | Buy | |
| Jun 10 | Oppenheimer | Initiated | Buy |
Seasonality
How IKT has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in IKT in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IKT is in one of them and how their past IKT trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IKT in an article yet. Here's the latest on the wider market.
About Inhibikase Therapeutics
Inhibikase Therapeutics is a pharmaceutical company developing treatments for pulmonary arterial hypertension, a rare and progressive disease that affects the blood vessels in the lungs. Its lead candidate, IKT-001, is an oral drug related to imatinib, a cancer medicine that has been used for many years. The company is running clinical trials of IKT-001 and has not yet sold a product. Its intended patients are people living with pulmonary arterial hypertension, and the company is based in Wilmington, Delaware.
- Headquarters
- Wilmington, DE